Compare Novartis AG (NVS) vs Quanta Services Inc (PWR) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Quanta Services (PWR) trades at $639.05, up 2.34% with strong technical momentum and bullish sentiment. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, supported by a record $53B backlog. Recent Q2 2026 earnings beat expectations with EPS of $4.24 versus $3.31 expected, while analyst consensus remains strongly bullish with a $811.14 price target.

PWR presents compelling growth potential driven by infrastructure demand and AI-related projects, though elevated valuation multiples (P/E 73.12) and significant capital expenditures pose risks. The company's strong backlog and margin expansion support upside, but investors should monitor execution on large-scale projects and competitive pressures in the construction sector.